According to Xuantai Pharmaceutical's announcement, the generic application for the company's product posaconazole enteric tablets was officially approved by the Colombian National Drug and Food Administration. The marketing license number is 2026072821. The dosage form is a tablet with a specification of 100 mg. This product is mainly used to treat aggressive aspergillus or candida infections. It is the first generic approved by the US FDA and the Chinese NMPA, and has been approved in many countries and regions. This approval indicates that the company is qualified to sell this product in the Colombian market. It is an important development for the company in the Latin American market. It has a positive impact on the company's long-term operations, and there is uncertainty about the impact on short-term performance.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.